

## CONCISE ARTICLE

[View Article Online](#)  
[View Journal](#) | [View Issue](#)

## Synthesis and antibacterial evaluation of anziaic acid and its analogues as topoisomerase I inhibitors†

Cite this: *Med. Chem. Commun.*, 2013, **4**, 1613Hao Lin,<sup>a</sup> Thirunavukkarasu Annamalai,<sup>b</sup> Priyanka Bansod,<sup>b</sup> Yuk-Ching Tse-Dinh<sup>b</sup> and Dianqing Sun<sup>\*a</sup>Received 26th August 2013  
Accepted 10th October 2013

DOI: 10.1039/c3md00238a

[www.rsc.org/medchemcomm](http://www.rsc.org/medchemcomm)

Naturally occurring anziaic acid has very recently been reported as a topoisomerase I inhibitor with antibacterial activity. Herein total synthesis of anziaic acid and its structural analogues is described and the preliminary structure–activity relationship (SAR) has been developed based on topoisomerase inhibition and whole cell antibacterial activity.

## Introduction

DNA topoisomerases are involved in the processes of DNA replication and transcription by controlling the topology of DNA.<sup>1,2</sup> Topoisomerases can be divided into type I and II subclasses according to the number of strands cut in the mechanism.<sup>3</sup> As topoisomerases are essential for normal cellular processes and cell proliferation, topoisomerase inhibitors can lead to cell death by binding and stabilizing cleavable topoisomerase–DNA complexes and preventing subsequent religation of the cleaved DNA strand. In this regard, topoisomerases represent attractive targets in antibacterial and anticancer drug discovery.<sup>4–7</sup> Clinically, semi-synthetic camptothecin derivatives topotecan and irinotecan inhibit human type IB topoisomerases and have been used for the treatment of various cancers.<sup>8,9</sup> In addition, the human type IIA topoisomerases are targets for anticancer drug classes of podophyllotoxins<sup>8</sup> (etoposide and teniposide) and anthracyclines.<sup>10</sup> Fluoroquinolones, one of the most successful antibiotic classes, exert their antibacterial activity by inhibiting type IIA topoisomerases (DNA gyrase and topoisomerase IV).<sup>11</sup>

The continuing emergence and prevalence of multidrug resistant bacterial pathogens, such as methicillin resistant *Staphylococcus aureus*,<sup>12</sup> extensively drug resistant tuberculosis,<sup>13</sup> fluoroquinolone resistant *Pseudomonas aeruginosa*,<sup>14</sup> and carbapenem resistant Enterobacteriaceae<sup>15</sup> have become an alarming and serious public health threat. Therefore, the new chemotype antibacterial agents with novel targets and mode of action are highly needed to combat pathogenic and drug

resistant microorganisms. Bacterial topoisomerase I belonging to the type IA topoisomerase subfamily has emerged as a promising target for developing new antibiotics and notably, currently no clinically used antibiotics target the type IA topoisomerase enzyme.<sup>4,6,16</sup> In this context, new, potent, and selective type IA topoisomerase inhibitors may be developed as effective antibacterial agents with therapeutic potential for bacterial pathogens resistant to current antibiotics.

Natural products have been one of the most important and successful sources of novel antibacterial agents.<sup>17–20</sup> Naturally occurring depsides which commonly exist in lichens showed promising and diverse biological activities. As examples, atranorin (Fig. 1) from lichen *Parmelia reticulata* was reported to exhibit antifungal activity against *S. rolsii* (ED<sub>50</sub> = 39.70 µg mL<sup>−1</sup>).<sup>21</sup> Jaboticabin from the fruit of jaboticaba (*Myrciaria cauliflora*) showed antioxidant and anti-inflammatory activities with therapeutic potential for the treatment of chronic obstructive pulmonary disease, as well as anticancer activity.<sup>22,23</sup> Anziaic acid,<sup>24–26</sup> a depside isolated from lichen *Hypotrachyna* sp., has very recently been found to exhibit inhibitory activity against bacterial (*Y. pestis* and *E. coli*) topoisomerase I and human topoisomerase II with




Fig. 1 Structures of selected naturally occurring bioactive depsides.

<sup>a</sup>Department of Pharmaceutical Sciences, The Daniel K. Inouye College of Pharmacy, University of Hawai'i at Hilo, 34 Rainbow Drive, Hilo, HI 96720, USA. E-mail: dianqing@hawaii.edu; Fax: +1-(808)-933-2974; Tel: +1-(808)-933-2960

<sup>b</sup>Department of Chemistry & Biochemistry, Florida International University, 11200 SW 8th Street, Miami, FL 33199, USA

† Electronic supplementary information (ESI) available: Experimental synthesis procedures and copies of <sup>1</sup>H and <sup>13</sup>C NMR spectra and HPLC chromatographs of synthetic intermediates, anziaic acid, and its analogues. See DOI: 10.1039/c3md00238a

IC<sub>50</sub> values of 14–19 and 35  $\mu\text{M}$ , respectively.<sup>27</sup> This natural product also demonstrated whole cell antibacterial activity against *Bacillus subtilis* and a membrane permeable strain (BAS3023) of *Escherichia coli* with minimum inhibitory activity (MIC) values of 6 and 12  $\mu\text{g mL}^{-1}$ , respectively.<sup>27</sup>

In our continued effort to discover novel chemotype antibacterial agents, we have employed emerging natural product leads as medicinal chemistry starting points, guided by the whole cell activity-driven approach and followed by target deconvolution and identification.<sup>28,29</sup> Recently, we initiated this topoisomerase I target-driven antibacterial research program. In particular, the promising bacterial topoisomerase I inhibition and whole cell antibacterial activity and the symmetrical and dimeric structural features of anziaic acid attracted our interest toward its resynthesis and biological evaluation of its structural analogues. Here the synthesis of anziaic acid and its analogues is described and the preliminary SAR is reported.


## Results and discussion

### Chemistry


Structurally, anziaic acid is a dimer of 2,4-dihydroxy-6-*n*-pentylbenzoic acid (**4**), and was previously synthesized by Asahina and

Hiraiwa<sup>30</sup> and Elix.<sup>31</sup> In this work, a convergent synthesis of anziaic acid was achieved from a commercially available starting material (Scheme 1). First, **2** was obtained from olivetol (**1**) via Vilsmeier–Haack reaction in moderate yield. The two phenol hydroxyl groups were protected with benzyl groups using potassium carbonate as the base, followed by oxidation with NaClO<sub>2</sub> to yield the phenol-protected acid product **3** in 61% yield. The acid-protected phenol (**5**) was synthesized following two sequential steps of oxidation of **2** and selective benzyl ester protection of carboxylic acid in **4**.<sup>31</sup> Compound **4** was also prepared by debenzoylation of **3** with higher yield and purity. Once the two key intermediates are in hand, subsequent selective condensation of **3** and **5** was performed<sup>32</sup> to afford benzyl protected dimeric precursor **6** in 64% yield by using trifluoroacetic acid anhydride as a condensation reagent. Finally, the benzyl groups were removed under palladium on carbon (Pd/C) and hydrogen atmosphere conditions to give anziaic acid in 95% yield.

Next, to investigate the effect of different substituents of the anziaic acid scaffold, such as the metal chelating salicylic acid motif and two lipophilic *n*-pentyl alkyl groups, a series of anziaic acid analogues (Scheme 2) were designed and synthesized following the same synthesis strategy as that used in the synthesis of anziaic acid. Briefly, the ester condensation of the



**Scheme 1** Total synthesis of anziaic acid: *reagents and conditions*: (a) DMF, POCl<sub>3</sub>, 0 °C to rt, 56%; (b) BnBr, K<sub>2</sub>CO<sub>3</sub>, acetone, reflux, 70%; (c) NaClO<sub>2</sub>, NaH<sub>2</sub>PO<sub>4</sub>, DMSO/H<sub>2</sub>O, 61% (**3**) and 50% (**4**); (d) Pd/C, H<sub>2</sub>, ethyl acetate, 97%; (e) BnBr, KHCO<sub>3</sub>, DMF, 92%; (f) (CF<sub>3</sub>CO)<sub>2</sub>O, toluene, 64%; (g) Pd/C, H<sub>2</sub>, ethyl acetate, 95%.



**Scheme 2** Synthesis of anziaic acid analogues **11a–d** and **14**: *reagents and conditions*: (a) **3** (for **13**), (CF<sub>3</sub>CO)<sub>2</sub>O, toluene, 57–85%; (b) Pd/C, H<sub>2</sub>, ethyl acetate, 80–100%; (c) SOCl<sub>2</sub>/acetone/DMAP, 1,2-dimethoxyethane, 0 °C to rt, 39%.


acid-protected phenol monomer **5**, **7**, **8**, or **12** and the phenol-protected acid monomer **3** or **9** yielded the benzyl protected dimers **10a–d** or **13**, which could be transformed into the corresponding acid-phenol products **11a–d** or **14** following the final debenzylation reaction.

In addition, to further expand the chemical diversity of existing anziaic acid derivatives and to investigate if this dimeric scaffold possesses any tractable topoisomerase inhibition and antibacterial activity, a focused compound collection with structural similarity to anziaic acid and with diverse linkers (e.g., amide or reverse amide in **15–17**, the azo N=N linkage in **18** and **19**, ester linker in **20** and **21**, C=C bond in **22** and **23**,  $-\text{OCH}_2$ -linkage in **24** and **25** and  $-\text{NHCH}_2$ -in **26**) was procured from Sigma-Aldrich (purity  $\geq 97\%$ , Fig. 2) and included in our screening. Structurally, these compounds possess a wide array of chemical functionalities and linkers, thus the screening data of these selected compounds may provide additional insights toward probing the specificity of structural features (e.g., the metal chelating motif, the dimeric scaffold, and the ester linker) of anziaic acid and establishing the preliminary SAR for enzyme and whole cell activity.

### Biological studies

Thus the synthesized anziaic acid and its analogues were evaluated for their ability to inhibit the topoisomerase enzyme (representative results shown in Fig. 3) and the growth of whole cell bacteria. The results are summarized in Table 1. In the *E. coli* topoisomerase I inhibition assay, our synthetic sample of anziaic acid exhibited reproducible topoisomerase I inhibition and antibacterial activity ( $\text{IC}_{50} = 17.7 \mu\text{M}$ ;  $\text{MIC} = 12.5 \mu\text{M}$ ) as the reported natural product sample isolated from lichen *Hypotrachyna* sp.<sup>27</sup> In contrast, the monomer of anziaic acid, 2,4-dihydroxy-6-pentylbenzoic acid (**4**), had no inhibitory activity against topoisomerase I and gyrase as well as whole cell bacteria. These data demonstrate that the dimeric scaffold bearing both phenyl rings is required for topoisomerase inhibition and antibacterial activity, ruling out the hydrolysis product **4** of anziaic acid being responsible for the activity.

In addition, compared with the prototype anziaic acid, benzyl fully protected compound **6** and acetal protected variant




**Fig. 3** Representative results of topoisomerase inhibition assays. (A) *E. coli* topoisomerase I inhibition assays with supercoiled plasmid DNA. (S) substrate. Lane 1: no enzyme; Lane 2: DMSO control; Lanes 3–6: 31.2, 23.6, 17.7, and 13.2  $\mu\text{M}$  (anziaic acid); Lanes 7–9: 1000, 500, and 250  $\mu\text{M}$  (**11d**); Lanes 10–12: 1000, 500, and 250  $\mu\text{M}$  (**11b**); Lanes 13–15: 1000, 500, and 250  $\mu\text{M}$  (**11a**). R: relaxed DNA; PR: partially relaxed DNA. (B) *E. coli* gyrase inhibition assays with relaxed plasmid DNA. Lane 1: no enzyme; Lane 2: DMSO control; Lanes 3–5: 62.5, 31.2, and 23.6  $\mu\text{M}$  (anziaic acid); Lanes 6–8: 1000, 500, and 250  $\mu\text{M}$  (**11d**); Lanes 9–11: 500, 250, and 125  $\mu\text{M}$  (**11b**); Lanes 12–14: 500, 250, and 125  $\mu\text{M}$  (**11a**).


**14** were inactive against *E. coli* topoisomerase I and DNA gyrase; compound **11d** with the absence of the carboxylic acid group showed very weak activity ( $\text{IC}_{50} = 250\text{--}500 \mu\text{M}$ ). Taken together, these results demonstrate that the absent or masked carboxylic acid group of anziaic acid had a detrimental effect on topoisomerase I and gyrase inhibition. This suggests that interaction of the acidic carboxylate with divalent metal ions at the active site might be required for inhibition of these types IA and IIA topoisomerase activities that require divalent ions for their catalytic activity.<sup>27</sup>

In terms of the effects of the *n*-pentyl lipophilic substituents of anziaic acid, removal of either one *n*-pentyl alkyl group in anziaic acid (compounds **11a** and **11b**) significantly reduced the inhibitory activities against topoisomerase I and DNA gyrase ( $\text{IC}_{50} = 250\text{--}500 \mu\text{M}$ ), which is about an 11–28 fold decrease relative to anziaic acid ( $\text{IC}_{50} = 17.7\text{--}23.6 \mu\text{M}$ ). Compound **11c**, with both *n*-pentyl groups removed, led to the complete loss of both enzyme inhibition and antibacterial activities. These data illustrate that the lipophilic alkyl groups significantly enhance both enzyme inhibitory and whole cell antibacterial activity and may play an important role in hydrophobic interactions with topoisomerase enzyme binding.

Interestingly, *in vitro* antibacterial evaluation revealed that **11d** with the carboxylic acid group absent ( $\text{MIC} = 3.12$  and  $25 \mu\text{M}$  against *B. subtilis* and a membrane permeable strain of *E. coli*, respectively) and the acetal protected anziaic acid **14** ( $\text{MIC} = 50 \mu\text{M}$  against *B. subtilis*) exhibited moderate to good antibacterial activity, despite very weak or no activity ( $\text{IC}_{50} = 500$  and  $>1000 \mu\text{M}$  for **11d** and **14**, respectively) in the topoisomerase



**Fig. 2** Structural analogues **15–26** of anziaic acid included in the screening.

**Table 1** Evaluation of anziaic acid and analogues against topoisomerases and whole cell bacteria<sup>a</sup>


Compound	$M_w$ (g mol <sup>-1</sup> )	cLogP <sup>b</sup>	<i>E. coli</i> topo I inhibition IC <sub>50</sub> (μM)	Human topo IIα inhibition IC <sub>50</sub> (μM)	<i>E. coli</i> DNA gyrase IC <sub>50</sub> (μM)	<i>B. subtilis</i> MIC (μM)	<i>E. coli</i> MIC (μM)
<b>4</b>	224.25	3.34	1000	>1000	>1000	>200	>200
<b>6</b>	700.86	—	>1000	>1000	>1000	>200	>200
Anziaic acid (isolated natural product) <sup>27</sup>	430.49	7.77	19	35	19	14	28
Anziaic acid (synthetic sample)	430.49	7.77	17.7	35	23.6	12.5	100
<b>10c</b>	560.59	9.25	>1000	>1000	>1000	>200	>200
<b>11a</b>	360.36	5.15	500	250	250	50	200
<b>11b</b>	360.36	6.05	250	125	250	50	>200
<b>11c</b>	290.23	3.44	>1000	>1000	>1000	>200	>200
<b>11d</b>	386.48	7.92	500	250	250	3.12	25
<b>14</b>	470.55	9.42	>1000	500	>1000	50	>200
<b>15</b>	351.44	6.34	>250	n.d.	n.d.	50–100	200
<b>16</b>	351.44	6.38	>250	n.d.	n.d.	100	400
<b>17</b>	321.67	2.75	>250	n.d.	n.d.	>800	>800
<b>18</b>	212.25	2.35	125–250	n.d.	n.d.	400	200–400
<b>19</b>	287.23	4.27	62.5–125	n.d.	n.d.	200	200
<b>20</b>	473.40	8.04	>250	n.d.	n.d.	>800	>800
<b>21</b>	310.43	7.30	>250	n.d.	n.d.	>800	>800
<b>22</b>	236.35	6.83	>250	n.d.	n.d.	>800	>800
<b>23</b>	280.28	3.12	>250	n.d.	n.d.	>800	>800
<b>24</b>	228.24	3.79	>250	n.d.	n.d.	>400	>400
<b>25</b>	182.17	2.76	>250	n.d.	n.d.	>400	>400
<b>26</b>	328.15	4.02	>250	n.d.	n.d.	200	200

<sup>a</sup> n.d. – not determined. <sup>b</sup> The *n*-octanol/water partition coefficient (LogP) of compounds was calculated using ChemBioOffice® Ultra version 12.0 from CambridgeSoft Corporation.


I enzyme assay. These data indicate that these two compounds may inhibit bacterial growth by a mechanism independent of topoisomerase inhibition, which does not require the presence of the carboxylic acid group.

Most of the analogues **15–26** with diverse linkers were not active in the test assays except that compounds **18** and **19** with the azo linker exhibited weak to moderate topoisomerase inhibition (IC<sub>50</sub> = 62.5–250 μM) and antibacterial activity (MIC = 200–400 μM).

Finally, these active compounds were also found to inhibit the human topoisomerase IIα enzyme in the same pattern as DNA gyrase and topoisomerase I. Further work is warranted to systematically optimize and evaluate advanced anziaic acid analogues in an effort to discover more selective bacterial topoisomerase I inhibitors with improved potency and specificity profiles and antibacterial therapeutic potential.

On the basis of these data, a preliminary SAR has been obtained and is shown in Fig. 4.

**Free carboxylic acid functionality** is essential for both topoisomerase and gyrase inhibition  
not for antibacterial activity



**The dimeric scaffold** is required for both topoisomerase and gyrase inhibition and antibacterial activity

**Lipophilic *n*-pentyl groups** enhance topoisomerase I and gyrase inhibition as well as antibacterial activity

**Fig. 4** Preliminary SAR.

## Conclusions

In summary, anziaic acid and its analogues were synthesized and evaluated against topoisomerases, DNA gyrase, and *Bacillus subtilis* as well as a membrane permeable strain of *E. coli*. Preliminary SAR studies demonstrate that the dimeric scaffold and the free carboxylate group of anziaic acid are essential in both topoisomerase and gyrase inhibition. However, the carboxylic acid functionality is not required for whole cell antibacterial activity. Furthermore, the lipophilic *n*-pentyl alkyl groups significantly enhance both topoisomerase enzyme inhibition and antibacterial activity.



## Experimental section

### Chemistry

**General.** All reagents and solvents were obtained from Sigma-Aldrich (St. Louis, MO) and Fisher Scientific (Hanover Park, IL) and were used without further purification. Reactions were monitored either by thin-layer chromatography (TLC) or by reverse-phase HPLC with a Shimadzu LC-20A series HPLC system. TLC was performed using glass plates pre-coated with silica gel (0.25 mm, 60 Å pore size, 230–400 mesh, Sorbent Technologies, GA) impregnated with a fluorescent indicator (254 nm). TLC plates were visualized by exposure to ultraviolet light (UV). Debenzylation reactions were done using a domnick hunter NITROX UHP-60H hydrogen generator, USA. Flash column chromatography was performed using a Biotage Isolera One system and a Biotage SNAP cartridge. Proton and carbon nuclear magnetic resonance ( $^1\text{H}$  and  $^{13}\text{C}$  NMR) spectra were recorded employing a Bruker AM-400 spectrometer. Chemical shifts were expressed in parts per million (ppm), and  $J$  values were expressed in Hertz. Mass spectra were recorded on a Varian 500-MS IT mass spectrometer using ESI. High-resolution mass spectra (HRMS) were recorded with a BioTOF II ESI mass spectrometer. The purity of compounds was determined by analytical HPLC using a Gemini, 3  $\mu\text{m}$ , C18, 110 Å column (50 mm  $\times$  4.6 mm, Phenomenex) and a flow rate of 1.0 mL  $\text{min}^{-1}$ . Gradient conditions: solvent A (0.1% trifluoroacetic acid in water) and solvent B (acetonitrile): 0–2.00 min 100% A, 2.00–7.00 min 0–100% B (linear gradient), 7.00–8.00 min 100% B, 8.00–9.00 min 0–100% A (linear gradient), 9.00–10.00 min 100% A, UV detection at 254 and 220 nm.

**Representative procedure for the synthesis of dimeric precursors.** To a stirred solution of benzyl 2,4-dihydroxy-6-pentylbenzoate (**5**) (94.3 mg, 0.3 mmol) and 2,4-bis(benzyloxy)-6-pentylbenzoic acid (**3**) (121.4 mg, 0.3 mmol) in dry toluene (3 mL) was slowly added trifluoroacetic acid anhydride (486  $\mu\text{L}$ , 3.45 mmol) at room temperature. The mixture was stirred overnight. The solvent was then removed under reduced pressure. The residue was purified by flash column chromatography (hexane : ethyl acetate = 97 : 3) to give **6** as a solid (135 mg, 64%).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ , ppm)  $\delta$  11.45 (s, 1H), 7.44–7.23 (m, 15H), 6.63 (d,  $J$  = 2.0 Hz, 1H), 6.50 (d, 2.4 Hz, 1H), 6.48 (d,  $J$  = 2.0 Hz, 1H), 6.38 (d,  $J$  = 2.4 Hz, 1H), 5.36 (s, 2H), 5.06 (s, 2H), 5.05 (s, 2H), 2.70–2.66 (m, 4H), 1.66–1.62 (m, 2H), 1.35–1.31 (m, 6H), 1.14–1.10 (m, 2H), 1.02–1.01 (m, 2H), 0.88 (t,  $J$  = 7.2 Hz, 3H), 0.79 (t,  $J$  = 7.2 Hz, 3H);  $^{13}\text{C}$  NMR (100.5 MHz,  $\text{CDCl}_3$ , ppm)  $\delta$  171.09, 166.06, 164.41, 161.02, 157.66, 155.27, 148.32, 143.94, 136.49, 136.35, 134.79, 129.10, 128.83, 128.78, 128.71, 128.57, 128.22, 128.11, 127.59, 127.54, 116.13, 115.62, 109.56, 108.78, 107.46, 98.24, 70.70, 70.20, 67.81, 36.84, 33.95, 31.92, 31.86, 31.71, 31.06, 22.60, 22.57, 14.08, 14.04; MS (ESI $^-$ ):  $m/z$  699.6 [ $\text{M} - \text{H}$ ] $^-$ ; HRMS (ESI $^+$ ) calcd for  $\text{C}_{45}\text{H}_{48}\text{O}_7$  ( $\text{M}^+$ ): 701.3473, found: 701.3472; HPLC purity: 100% (254 nm),  $t_{\text{R}}$ : 8.91 min; 100% (220 nm),  $t_{\text{R}}$ : 8.91 min.

**Representative procedure for debenzylation of dimers and synthesis of anziaic acid.** A solution of benzyl 4-((2,4-bis(benzyloxy)-6-pentylbenzoyl)oxy)-2-hydroxy-6-pentylbenzoate (**6**) (135 mg, 0.19 mmol) in ethyl acetate (5 mL) was treated with 10% Pd/C (38 mg). The mixture was stirred at room temperature

under 1 bar of  $\text{H}_2$  atmosphere for *ca.* 2 h. The reaction was stopped once it was complete (monitored by HPLC). The mixture was filtered through Celite and washed with ethyl acetate. The combined organic layer was evaporated under reduced pressure (the water bath temperature was kept below 30  $^\circ\text{C}$ ) to give anziaic acid as a white solid (78.6 mg, 95%).  $^1\text{H}$  NMR (400 MHz,  $\text{CD}_3\text{OD}$ , ppm)  $\delta$  6.62 (d,  $J$  = 2.4 Hz, 1H), 6.56 (d,  $J$  = 2.0 Hz, 1H), 6.27 (d,  $J$  = 2.0 Hz, 1H), 6.22 (d,  $J$  = 2.4 Hz, 1H), 2.92 (t,  $J$  = 7.2 Hz, 2H), 2.86 (t,  $J$  = 7.6 Hz, 2H), 1.62–1.60 (m, 4H), 1.34–1.32 (m, 8H), 0.91–0.86 (m, 6H);  $^{13}\text{C}$  NMR (100.5 MHz,  $\text{CD}_3\text{OD}$ , ppm)  $\delta$  173.89, 170.41, 166.05, 164.34, 164.14, 154.90, 149.36, 149.04, 116.22, 113.16, 112.23, 109.03, 105.22, 102.01, 37.73, 36.79, 33.21, 33.13, 32.99, 32.62, 23.60, 23.46, 14.44, 14.38; MS (ESI $^-$ ):  $m/z$  429.3 [ $\text{M} - \text{H}$ ] $^-$ ; HRMS (ESI $^+$ ) calcd for  $\text{C}_{24}\text{H}_{30}\text{O}_7$  ( $\text{M} + \text{Na}^+$ ): 453.1884, found: 453.1887; HPLC purity: 100% (254 nm),  $t_{\text{R}}$ : 7.54 min; 100% (220 nm),  $t_{\text{R}}$ : 7.54 min.

The spectroscopic data of synthetic anziaic acid are consistent with those of the isolated anziaic acid natural product from lichen *Hypotrachyna* sp.<sup>27</sup>

Synthesis of other structural analogues of anziaic acid is described in the ESI.<sup>†</sup>

**Topoisomerase inhibition assays.** The topoisomerase assays were performed as previously described.<sup>27</sup> The  $\text{IC}_{50}$  values were determined from an average of experiments repeated at least twice. Briefly, inhibition of relaxation activity of 10 ng of *E. coli* topoisomerase I was assayed with 250 ng of supercoiled pBAD/Thio plasmid DNA substrate purified by a CsCl gradient. The relaxation reaction was carried out in 20  $\mu\text{L}$  of 10 mM Tris-HCl, pH 8.0, 50 mM NaCl, 0.1 mg  $\text{mL}^{-1}$  gelatin with 0.5 mM  $\text{MgCl}_2$ . After 30 min at 37  $^\circ\text{C}$ , the reactions were terminated and analyzed by agarose gel electrophoresis.

Human topoisomerase II $\alpha$  (from TopoGen) relaxation assay and *E. coli* DNA gyrase (from New England BioLab) supercoiling assay were carried out as recommended by the suppliers. A relaxed plasmid DNA substrate for DNA gyrase was purchased from New England BioLabs.

**Antibacterial testing.** The MICs of compounds against different bacterial strains grown in cation-adjusted Mueller-Hinton Broth were measured with standard microdilution procedures.<sup>27</sup> Complete growth inhibition was recorded after 24 h in a 37  $^\circ\text{C}$  incubator.

## Acknowledgements

This work was supported in part by the National Institutes of Health Grants P20RR016467, P20GM103466, and R15AI092315 (D.S.) as well as R01AI069313 (Y.T.). We also thank Dr Benjamin Clark and Dr Robert Borris for the assistance with collecting the HRMS data of the synthesized compounds.

## Notes and references

- 1 J. C. Wang, *Nat. Rev. Mol. Cell Biol.*, 2002, **3**, 430–440.
- 2 S. M. Vos, E. M. Tretter, B. H. Schmidt and J. M. Berger, *Nat. Rev. Mol. Cell Biol.*, 2011, **12**, 827–841.
- 3 J. E. Deweese and N. Osheroff, *Nucleic Acids Res.*, 2009, **37**, 738–748.

- 4 Y. Pommier, *ACS Chem. Biol.*, 2013, **8**, 82–95.
- 5 Y. Pommier, E. Leo, H. Zhang and C. Marchand, *Chem. Biol.*, 2010, **17**, 421–433.
- 6 Y.-C. Tse-Dinh, *Nucleic Acids Res.*, 2009, **37**, 731–737.
- 7 Y.-C. Tse-Dinh, *Infect. Disord.: Drug Targets*, 2007, **7**, 3–9.
- 8 J. T. Hartmann and H.-P. Lipp, *Drug Saf.*, 2006, **29**, 209–230.
- 9 Y. Pommier, *Nat. Rev. Cancer*, 2006, **6**, 789–802.
- 10 C. Bailly, *Chem. Rev.*, 2012, **112**, 3611–3640.
- 11 D. C. Hooper, *Clin. Infect. Dis.*, 2000, **31**, S24–S28.
- 12 H. Grundmann, M. Aires-de-Sousa, J. Boyce and E. Tiemersma, *Lancet*, 2006, **368**, 874–885.
- 13 D. Falzon, E. Jaramillo, H. J. Schünemann, M. Arentz, M. Bauer, J. Bayona, L. Blanc, J. A. Caminero, C. L. Daley, C. Duncombe, C. Fitzpatrick, A. Gebhard, H. Getahun, M. Henkens, T. H. Holtz, J. Keravec, S. Keshavjee, A. J. Khan, R. Kulier, V. Leimane, C. Lienhardt, C. Lu, A. Mariandyshev, G. B. Migliori, F. Mirzayev, C. D. Mitnick, P. Nunn, G. Nwagboniwe, O. Oxlade, D. Palmero, P. Pavlinac, M. I. Quelapio, M. C. Raviglione, M. L. Rich, S. Royce, S. Rüsch-Gerdes, A. Salakaia, R. Sarin, D. Sculier, F. Varaine, M. Vitoria, J. L. Walson, F. Wares, K. Weyer, R. A. White and M. Zignol, Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis, 2011 Update, World Health Organisation, Geneva, 2011.
- 14 D. I. Hsu, M. P. Okamoto, R. Murthy and A. Wong-Beringer, *J. Antimicrob. Chemother.*, 2005, **55**, 535–541.
- 15 M. J. Schwaber and Y. Carmeli, *J. Am. Med. Assoc.*, 2008, **300**, 2911–2913.
- 16 V. Nagara, D. Siker and J. Pain, *Curr. Pharm. Des.*, 2002, **8**, 1995–2007.
- 17 A. C. Abreu, A. J. McBain and M. Simões, *Nat. Prod. Rep.*, 2012, **29**, 1007–1021.
- 18 K. Lewis, *Nat. Rev. Drug Discovery*, 2013, **12**, 371–387.
- 19 J. Clardy, M. A. Fischbach and C. T. Walsh, *Nat. Biotechnol.*, 2006, **24**, 1541–1550.
- 20 G. M. Cragg and D. J. Newman, *Biochim. Biophys. Acta*, 2013, **1830**, 3670–3695.
- 21 M. Goel, P. Dureja, A. Rani, P. L. Uniyal and H. Laatsch, *J. Agric. Food Chem.*, 2011, **59**, 2299–2307.
- 22 K. A. Reynertson, A. M. Wallace, S. Adachi, R. R. Gil, H. Yang, M. J. Basile, J. D'Armiento, I. B. Weinstein and E. J. Kennelly, *J. Nat. Prod.*, 2006, **69**, 1228–1230.
- 23 S.-B. Wu, J. Wu, Z. Yin, J. Zhang, C. Long, E. J. Kennelly and S. Zheng, *J. Agric. Food Chem.*, 2013, **61**, 4035–4043.
- 24 Y. Asahina and M. Hiraiwa, *Ber. Dtsch. Chem. Ges.*, 1935, **68**, 1705–1708.
- 25 J. A. Elix and J. H. Wardlaw, *Aust. J. Chem.*, 1997, **50**, 1145–1150.
- 26 C. H. Fox and S. Huneck, *Phytochemistry*, 1970, **9**, 2057.
- 27 B. Cheng, S. Cao, V. Vasquez, T. Annamalai, G. Tamayo-Castillo, J. Clardy and Y.-C. Tse-Dinh, *PLoS One*, 2013, **8**, e60770.
- 28 D. Sun, J. G. Hurdle, R. Lee, R. Lee, M. Cushman and J. M. Pezzuto, *ChemMedChem*, 2012, **7**, 1541–1545.
- 29 L. Shen, M. M. Maddox, S. Adhikari, D. F. Bruhn, M. Kumar, R. E. Lee, J. G. Hurdle, R. E. Lee and D. Sun, *J. Antibiot.*, 2013, **66**, 319–325.
- 30 Y. Asahina and M. Hiraiwa, *Ber. Dtsch. Chem. Ges.*, 1937, **70**, 1826–1828.
- 31 J. A. Elix, *Aust. J. Chem.*, 1974, **27**, 1767–1779.
- 32 P. Wang, Z. Zhang and B. Yu, *J. Org. Chem.*, 2005, **70**, 8884–8889.